Social media

Antibody-drug conjugates (ADCs) are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Even the smallest impurity can skew results. Discover how adv...

Meet ICON experts at the AASLD to learn how ICON partners with sponsors, investigators, patients and other collaborators to deliver strategic, data-driven solutions for MASH and hepatology studies. https://ow.ly/6a6M50X8...

Journals & Congresses offers rejection rate insights. You can review rejection rates by journal, helping target the best fit for your submission. Check out our interactive dashboard and see for yourself. https://ow.ly/ex...

SLRs are more than academic exercises—they’re strategic tools that guide regulatory, clinical, and commercial decisions. ICON’s expert team delivers tailored, publication-ready reviews that meet your goals and timelines....

Recruitment in rare disease trials is never easy, especially with complex endpoints and direct competition. Discover how ICON helped a sponsor overcome these hurdles in two pivotal HCM trials through targeted site selec...

A 2025 ICON survey reflected the persistent use of conventional trial formats for emerging obesity drugs with multi-indication potential. However, nontraditional trial formats can be better suited to multi-indication dev...

It is now common to pursue multiple indications for a single drug. But what is the most strategic approach to accelerating cross-indication approvals? Read the article for ICON's insights. https://ow.ly/a5po50XapWF

ICON will be participating in ACOP 2025 in Aurora, Colorado, where we will introduce Yi Zhang, our new Scientific Director of PK in the Pharmacometrics Department. Yi brings extensive expertise in PK/PD modeling, disea...

What does successful biomarker integration look like in early-phase CNS trials? Discover how leading researchers are applying imaging, wet, genetic, and digital biomarkers to enrich populations and improve decision-maki...

One billion people worldwide will be living with obesity by 2030. Connect with us at Obesity Week, booth #520 on Nov 4–7 to learn how ICON supports obesity trials with market intelligence, regulatory expertise, and ready...

Meet ICON at #ObesityWeek, Nov 4–7 at booth \#520 to arrange time with our experts and explore how we support next-gen obesity trials. From proof of concept to large portfolios, ICON delivers market intelligence and read...

ICON invites you to attend a presentation by Arjen Akkerman, Senior Director, Accelerated Pharmaceutical Solutions on 28 October at 11:35 am at Messe Frankfurt. In his session, “From collaboration to commitment: Strengt...